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The JAK2 V617F mutation, which provides a growth and
survival advantage to hematopoietic clones, is the most
commonly observed driver mutation in myeloproliferative
neoplasms (MPNs), present in more than 95% of
polycythemia vera patients and in 50–60% of essential
thrombocythemia and primary myelofibrosis (PMF) patients.
This mutation is also present in a smaller but significant pro-
portion of patients with myelodysplastic syndrome (MDS)/
MPN. The diagnosis of these hematopoietic malignancies is
multifactorial and dependent upon clinical presentation,
peripheral blood and bone marrow morphological features,
other hematological features, and increasingly, the underly-
ing molecular genetic signature [1,2]. A sporadically
observed trigger for requesting JAK2 V617F analysis is for
investigation of a thrombocytopenia as a manifestation of
PMF or MDS/MPN; however, the causes of thrombocytopenia
are many and can be divided into decreased bone marrow
platelet production, increased peripheral platelet
destruction, increased splenic sequestration, and dilution
categories [3]. Given the relatively low incidence of PMF
or MDS/MPN compared with other causes of thrombocytope-
nia, the clinical value of screening for the JAK2 V617F
mutation in such cases was assessed.A retrospective audit was performed on JAK2 V617F
requests to a central hematological malignancy molecular
diagnostic center. From January 2006 to May 2016 inclusive,
there were 13,411 requests for JAK2 V617F mutation analy-
sis. Of these requests, 186 (1.4%) had clinical details of a
thrombocytopenia. A screening assay capable of detecting
a 1% mutant allele burden did not detect the JAK2 V617F
in any of these 186 patients.
It must be noted that rare cases of the development of
JAK2 V617F-positive essential thrombocythemia in preexist-
ing thrombocytopenic disorders have been documented
where the resultant increase in platelet count has been clin-
ically beneficial [4,5]. In addition, autoimmune disorders,
including immune thrombocytopenia, are increasingly spec-
ulated to be risk factors for the subsequent development of
an MPN [6]. However, the aforementioned observation in
patients with isolated thrombocytopenia suggests that
investigation for JAK2 V617F is not routinely indicated in
the absence of other clinical and laboratory features of an
MPN. This brief but informative audit confirms the require-
ment for considered selection of laboratory tests for the
investigation of thrombocytopenia.
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